Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center

References

• Jafri SM, Gordon SC. Epidemiology of Hepatitis C. Clin Liver Dis (Hoboken). 2018;12(5):140–142.
   PubMedGoogle Scholar
• Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology. 2006;43(5):915–922.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Elbaz T, Elsharkawy A, et al. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev anti Infect Ther. 2018;16(4):345–350.
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–S57.
   PubMed Web of Science ®Google Scholar
• Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553–562.
   PubMed Web of Science ®Google Scholar
• Gomaa A, Allam N, Elsharkawy A, et al. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med. 2017;9:17–25.
   PubMed Web of Science ®Google Scholar
• El-Zenati F, Way A. Knowledge and prevalence of Hepatitis C. Egypt demographic and health survey 2008. [cited 2021 May 10]. Available from: https://dhsprogram.com/pubs/pdf/FR220/FR220.pdf
   Google Scholar
• El Raziky M, Fathalah WF, El-Akel WA, et al. The effect of peginterferon alpha-2a vs. Peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single Centre egyptian study. Hepat Mon. 2013;13(5):e10069.
   PubMed Web of Science ®Google Scholar
• Esmat G, El Kassas M, Hassany M, et al. How to optimize HCV therapy in genotype 4 patients. Liver Int. 2013;33 Suppl 1 (Suppl 1):41–45.
   PubMedGoogle Scholar
• El Kassas M, Elbaz T, Hafez E, et al. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001–2012. MMWR Morb Mortal Wkly Rep. 2012;61(29):545–549.
   PubMedGoogle Scholar
• Esmat G, El Kassas M, Hassany M, et al. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int. 2014;34 Suppl 1 (Suppl 1):24–28.
   PubMedGoogle Scholar
• Esmat G, El Raziky M, El Kassas M, et al. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int. 2012;32 Suppl 1 (Suppl 1):146–150.
   PubMedGoogle Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
   PubMed Web of Science ®Google Scholar
• Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. J Adv Res. 2015;6(3):301–310.
   PubMed Web of Science ®Google Scholar
• Behzadifar M, Gorji HA, Rezapour A, et al. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. J Virus Erad. 2019;5(2):116–121.
   PubMed Web of Science ®Google Scholar
• Esmat G, Elbaz T, Elsharkawy A, et al. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev anti Infect Ther. 2020;18(7):637–642.
   PubMed Web of Science ®Google Scholar
• El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat. 2017;24(4):262–267.
   PubMed Web of Science ®Google Scholar
• Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014;15(2):45–52.
   PubMed Web of Science ®Google Scholar
• Estes C, Abdel-Kareem M, Abdel-Razek W, et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42(6):696–706.
   PubMed Web of Science ®Google Scholar
• Omran D, Alboraie M, Zayed RA, et al. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 2018;24(38):4330–4340.
   PubMed Web of Science ®Google Scholar
• Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421–431.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Alboraie M, Omran D, et al. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment Centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12(12):1265–1272.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Funk AL, Abd El Latif Y, et al. Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt. Aliment Pharmacol Ther. 2018;47(11):1564–1566.
   PubMed Web of Science ®Google Scholar
• Elsharkawy A, Fouad R, El Akel W, et al. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther. 2017;45(5):681–687.
   PubMed Web of Science ®Google Scholar
• Elbaz T, Elserafy M, Elakel W, et al. Serious adverse events with sofosbuvir combined with interferon and ribavirin: real-life Egyptian experience. J Interferon Cytokine Res. 2017;37(8):348–353.
   PubMed Web of Science ®Google Scholar
• Eletreby R, Elakel W, Said M, et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37(4):534–541.
   PubMed Web of Science ®Google Scholar
• Shiha G, Esmat G, Hassany M, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2019;68(4):721–728.
   PubMed Web of Science ®Google Scholar
• Ahmed OA, Kaisar HH, Badawi R, et al. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. IDR. 2018;11:295–298.
   Google Scholar
• El Kassas M, Omran D, Elsaeed K, et al. Spur-of-the-moment modification in national treatment policies leads to a surprising HCV viral suppression in all treated patients: real-life egyptian experience. J Interferon Cytokine Res. 2018;38(2):81–85.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Alboraie M, Omar H, et al. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results. J Med Virol. 2022;94(2):667–674.
   PubMed Web of Science ®Google Scholar
• Said EM, Abdulaziz BA, El Kassas M, et al. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol. 2020;165(7):1633–1639.
   PubMed Web of Science ®Google Scholar
• Bonnard P, Elsharkawy A, Zalata K, et al. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. J Viral Hepat. 2015;22(3):245–253.
   PubMed Web of Science ®Google Scholar
• Afify SM, Tabll A, Nawara HM, et al. Five fibrosis biomarkers together with serum ferritin level to diagnose liver fibrosis and cirrhosis. Clin Lab. 2018;64(10):1685–1693.
   PubMed Web of Science ®Google Scholar
• Gamil M, Alboraie M, El-Sayed M, et al. Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. J Med Virol. 2018;90(6):1080–1086.
   PubMed Web of Science ®Google Scholar
• Abdel Alem S, Elsharkawy A, El Akel W, et al. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol. 2019;13(10):1009–1016.
   PubMed Web of Science ®Google Scholar
• Fouad R, Elbaz T, Abdel Alem S, et al. Evaluation of accuracy of elastography point quantification versus other non-invasive modalities in staging of fibrosis in chronic hepatitis C virus patients. Eur J Gastroenterol Hepatol. 2018;30(8):882–887.
   PubMed Web of Science ®Google Scholar
• Hu KQ, Kyulo NL, Lim N, et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99(5):860–865.
   PubMed Web of Science ®Google Scholar
• Fouad R, Elsharkawy A, Abdel Alem S, et al. Clinical impact of serum alpha-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol. 2019;31(9):1129–1134.
   PubMed Web of Science ®Google Scholar
• Badawi R, Alboraie M, Abd-Elsalam S, et al. Serum alpha-fetoprotein levels and response to direct antiviral therapy in patients with chronic hepatitis C: real-world results from 1716 patients in Egypt. EMIDDT. 2019;19(7):1005–1011.
   Google Scholar
• El Kassas M, Alboraie M, Mostafa A, et al. After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. J Clin Lab Anal. 2018;32(3):e22296.
   PubMed Web of Science ®Google Scholar
• Youssef NF, El Kassas M, Farag A, et al. Health-related quality of life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without interferon: a prospective observational study in Egypt. BMC Gastroenterol. 2017;17(1):18.
   PubMedGoogle Scholar
• Ar NZ, Raafat AM, Elmasry S, et al. Promotor methylation: does it affect response to therapy in chronic hepatitis C (G4) or fibrosis? Ann Hepatol. 2014;13(5):518–524.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address, eee, clinical practice guidelines panel C, representative EGB, panel m. EASL recommendations on treatment of hepatitis C: final update of the series(). J Hepatol. 2020;73(5):1170–1218.
   PubMed Web of Science ®Google Scholar
• Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin . Scand J Gastroenterol. 2009;44(12):1487–1490.
   PubMed Web of Science ®Google Scholar
• Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–136.
   PubMed Web of Science ®Google Scholar
• Pockros PJ. Black box warning for possible HBV reactivation during DAA therapy for chronic HCV infection. Gastroenterol Hepatol (N Y). 2017;13(9):536–540.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Yeh ML, Huang CF, Hsieh MH, et al. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32(10):1754–1762.
   PubMed Web of Science ®Google Scholar
• Liu CH, Liu CJ, Su TH, et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect Dis. 2017;4(1):ofx028.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Shimakawa Y, Ali-Eldin Z, et al. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: a cohort study from Egypt and meta-analysis of published data. Liver Int. 2018;38(12):2159–2169.
   PubMed Web of Science ®Google Scholar
• Gobran ST, Ancuta P, Shoukry NH. A tale of two viruses: immunological insights into HCV/HIV coinfection. Front Immunol. 2021;12:726419.
   PubMed Web of Science ®Google Scholar
• Abdelaziz H, Omar H, Khalil M, et al. Real-life experience of treating HCV coinfection among HIV-infected population in Egypt: single-center experience. Expert Rev anti Infect Ther. 2021;1–7. DOI:10.1080/14787210.2022.2004117
   Web of Science ®Google Scholar
• Eletreby R, Esmat G, Elsharkawy A, et al. HCV/HIV coinfected Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. Trans R Soc Trop Med Hyg. 2021;trab106.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Craxi A, Zuckerman E, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat. 2017;24(11):936–943.
   PubMed Web of Science ®Google Scholar
• Perricone G, Duvoux C, Berenguer M, et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. Liver Int. 2018;38(12):2170–2177.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Abdeen N, Omran D, et al. Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e877–e882.
   PubMedGoogle Scholar
• El Kassas M, Alboraie M, Elsaeed K, et al. Real-life efficacy of 5 different antiviral regimens for treatment of chronic hepatitis C with normal liver enzymes. Am J Ther. 2018;25(6):e776–e779.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.
   PubMed Web of Science ®Google Scholar
• Benitez-Gutierrez L, Barreiro P, Labarga P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17(9):1215–1223.
   PubMed Web of Science ®Google Scholar
• Abdel-Moneim A, Aboud A, Abdel-Gabaar M, et al. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int. 2018;12(4):348–355.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Alboraie M, El Badry M, et al. Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: a multicenter study. Int J Infect Dis. 2020;96:367–370.
   PubMed Web of Science ®Google Scholar
• Elbaz T, Abdo M, Omar H, et al. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. J Med Virol. 2019;91(2):272–277.
   PubMed Web of Science ®Google Scholar
• El Kassas M, El Sheemy R, Alboraie M, et al. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med. 2019;10(2):295–302.
   PubMed Web of Science ®Google Scholar
• Conti F, Brillanti S, Buonfiglioli F, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24(6):454–463.
   PubMed Web of Science ®Google Scholar
• Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856–865.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Funk AL, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis. J Viral Hepat. 2018;25(6):623–630.
   PubMed Web of Science ®Google Scholar
• Reig M, Boix L, Marino Z, et al. Liver cancer emergence associated with antiviral treatment: an immune surveillance failure? Semin Liver Dis. 2017;37(2):109–118.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Tawheed A, Eltabbakh M, et al. Hepatitis C antiviral therapy in patients with successfully treated hepatocellular carcinoma: dancing with wolves. J Hepatocell Carcinoma. 2019;6:183–191.
   PubMed Web of Science ®Google Scholar
• Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2021;gutjnl-2020-323663.
   PubMed Web of Science ®Google Scholar
• El-Sayed M, Abdellatif Z, Elsharkawy A, et al. Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection. 2020;48(6):913–922.
   PubMed Web of Science ®Google Scholar
• Li M, Chen J, Fang Z, et al. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and Meta-analysis. Virol J. 2019;16(1):34.
   PubMedGoogle Scholar
• Cox-North P, Hawkins KL, Rossiter ST, et al. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun. 2017;1(3):248–255.
   PubMed Web of Science ®Google Scholar
• Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65(1):40–47.
   PubMed Web of Science ®Google Scholar
• Taneja S, Duseja A, De A, et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63(5):1334–1340.
   PubMed Web of Science ®Google Scholar
• Eletreby R, El-Serafy M, Anees M, et al. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int. 2020;40(4):797–805.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Pileri SA, et al. Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCVi. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39(1):2–17.
   PubMedGoogle Scholar
• Mohammed RH, ElMakhzangy HI, Gamal A, et al. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol. 2010;29(12):1373–1380.
   PubMed Web of Science ®Google Scholar
• Saleh LM, Canioni D, Shamaa S, et al. High prevalence of Hepatitis C Virus among B-cell Non Hodgkin lymphoma patients in Mansoura Region (Egypt), ANRS 12263 study. Mediterr J Hematol Infect Dis. 2019;11(1):e2019011.
   PubMedGoogle Scholar
• El Kassas M, Hegazy OM, Salah EM. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations. World J Hepatol. 2020;12(10):841–849.
   PubMed Web of Science ®Google Scholar
• Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant. 2013;13 Suppl 3(Suppl 3):55–66.
   PubMedGoogle Scholar
• El Kassas M, Wifi MN, Mahdy R, et al. Herpes zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: a case series. Arab J Gastroenterol. 2017;18(1):39–41.
   PubMed Web of Science ®Google Scholar
• Karaivazoglou K, Tsermpini EE, Assimakopoulos K, et al. Sexual functioning in patients with chronic hepatitis C: a systematic review. Eur J Gastroenterol Hepatol. 2017;29(11):1197–1205.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Salah E, Gad A, et al. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr Med Res Opin. 2021;37(6):967–972.
   PubMed Web of Science ®Google Scholar
• Attia D, El Saeed K, Elakel W, et al. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment Pharmacol Ther. 2018;47(9):1296–1305.
   PubMed Web of Science ®Google Scholar
• Soliman Z, El Kassas M, Elsharkawy A, et al. Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets. 2021;32(3):383–388.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Alboraie M, Naguib M, et al. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol. 2019;30(8):708–713.
   PubMed Web of Science ®Google Scholar
• Gaafar AE, Abd El-Aal A, Alboraie M, et al. Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease. Egypt Heart J. 2019;71(1):21.
   PubMedGoogle Scholar